Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-786 for Agitation in Alzheimer's Dementia
NCT02442778Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2015
- Primary completion
- Aug 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of deudextromethorphan in agitation (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Cohen-Mansfield Agitation Inventory Composite Score at 12 weeks. Started Nov 2015; status: completed.
02
Drugs
deudextromethorphan
03
Conditions
agitation
Beyond the preview
Go deeper on NCT02442778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02442778.